ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OPTI Optibiotix Health Plc

17.75
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 17.75 17.50 18.00 17.75 17.75 17.75 22 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 6.25 16.19M
Optibiotix Health Plc is listed in the Noncomml Resh Organizations sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 17.75p. Over the last year, Optibiotix Health shares have traded in a share price range of 5.75p to 43.50p.

Optibiotix Health currently has 91,190,661 shares in issue. The market capitalisation of Optibiotix Health is £16.19 million. Optibiotix Health has a price to earnings ratio (PE ratio) of 6.25.

Optibiotix Health Share Discussion Threads

Showing 44951 to 44969 of 147550 messages
Chat Pages: Latest  1810  1809  1808  1807  1806  1805  1804  1803  1802  1801  1800  1799  Older
DateSubjectAuthorDiscuss
18/10/2018
12:33
Rayrac what on earth are you going on about OPTI trying it on? Your posts are tenuous to say the least, of a negative nature, which is fine but please do elaborate.
dazah
18/10/2018
12:22
That’s a shame nobby you should think that, but I’m not too concerned. As long as LPLDL gets no recognition from the medical fraternity or the NHS, then Opti appear to be trying it on. That doesn’t seem to be very fair on the investing population.
rayrac
18/10/2018
11:58
>> slarty

Yes he has reverted into being a troll which is very sad. At one stage many moons ago he actually made some sensible contributions. No longer....

nobbygnome
18/10/2018
11:14
Dazah imho the recent spike to 130p was technically driven as the share price broke above a key resistance area and 30 Month decending pattern.

The share price has recently returned back to that pattern and back to type.

The PA we are seeing today is normal for OPTI.

john henry
18/10/2018
10:35
To a degree kmann that probably led to this overheating in August.
dazah
18/10/2018
10:34
Kmann so your complaint is that a company that is doing well is telling everyone about it... In terms of ceo activity I have to say I've seen worse.
1bokke
18/10/2018
10:22
This company has more social media hype than Kim Kardashian, Even KK wouldn't be seen dead in a proactive interview!
kmann
18/10/2018
09:42
Parob - Seed seem to have the marketing sussed.

Catch - keep up, that was out on Monday. Soz :(

m4rtinu
17/10/2018
17:12
Good update on proactive on progress of the licensing agreements:

hxxp://www.biotech-capital.com/companies/news/207210/optibiotix-boss-stephen-ohara-highlights-recent-direct-share-purchases-in-proactive-interview-207210.html

catch007
17/10/2018
15:42
Slarty dear boy, I don't want you to get any more conceited than you appear. ;) but you’re beginning sound/feel like a very very, close relative of SoH..surely not?

“Come and meet me for a pint and i'll teach you how to woo people and have them eating out of your hand. My forte...lol”

LOL!

rayrac
17/10/2018
15:14
not sold any slarty mate keep the faith it could be worse ask jack uk oil and garbage and bpc lol
manc10
17/10/2018
14:50
Jack, Don't make lies up, i didn't threaten you. I have a lot of respect for the elderly, we owe so many so much. I invited you for a drink and a chat.
slartybartfaster
17/10/2018
14:45
I thought you have sold up and left us. Welcome back manc you manc. lol
slartybartfaster
17/10/2018
13:33
The aim of this study was to investigate the cholesterol reducing capacity of Lactobacillus plan- tarum ECGC 13110402 in healthy, normal to mildly hypercholesterolaemic adults. Primary efficacy outcomes included effect on blood lipids, safety and tolerance; secondary outcomes included blood pressure, immune biomarkers, gut microbiota analysis and metabonome changes.This study used a strain, Lactobacillus plantarum ECGC 13110402, identified after in vitro screening of 353 microbial strains for mechanisms of action known to influence cholesterol reduction and having high simulated gut survivability. The in vitro screening identified Lacto- bacillus plantarum ECGC 13110402 as having high BSH activity, ability to reduce cholesterol, high preferential resistance to gastric, pancreatic, and bile acids and high survivability on freeze drying. Adopting a systematic approach to selecting microbial strains with known mechanisms of action (bile salt hydrolysis) relevant to established disease biomarkers (choles- terol), introduces a baseline rationale to probiotic strain selection, controls the effects of strain variability commonly described in previous studies [7], while increasing the likelihood of reli- able outcomes in human studies.The results of the study demonstrate biologically and/ or statistically significant effects across several CHD risk factors, particularly LDL, HDL, and blood pressure, in normal to mildly hypercholesterolaemic subjects.One of the primary targets for reducing cardiovascular risk is LDC-C. Study results suggest a consistent pattern for reduction in the active group compared to the placebo across 0–6, 6–12, and 0–12 week periods. Changes in LDL-C varied from 0.24mmol/l (7.2%) in the all sub- ject group to 0.39mmol/l (13.9%) in the N-TC group (P = 0.03). Whilst individual group and subgroup analysis demonstrated variations in statistical significance, there was a consistent trend towards lower LDL values across all active groups. These reductions have potential clini- cal significance as a 1% reduction in serum cholesterol has been associated with a lessening of artery disease risk by 2–3% [18].Correlation analyses to examine changes in TC levels between two time points showed a statistically significance (P = 0.04) reduction in TC between baseline and 6 weeks in the active group. This effect was not seen in the placebo group. There was a similar consistent decrease in TC levels when comparing the average active treatment to the placebo. This ranged from 0.12mmol/l (2.3%) in the all subject group to a statistically significant 2.44mmol/l reduction (36.7%, P = 0.045) in the H-TC group. TC reductions of 0.19mmol/l (4.2%) and 0.23mmol/l (4.17%) were seen in the N-TC and M-TC group respectively.http://centaur.reading.ac.uk/74389/1/journal.pone.0187964.pdf
riskybusiness1
17/10/2018
13:18
rayrat you mug
manc10
17/10/2018
13:12
Threats on the internet! Oh dear.
rayrac
17/10/2018
12:50
humph,
He’s a legend in his own mind
In reality though he’s a leg end when picking his shares

judijudi
17/10/2018
12:49
Rayrac, show me where this Israeli test says that Optibiotix's LPLDL does not survive the digestive journey and is absolutely pointless. Show me your proof!There are probably thousands upon thousands of papers published stating effective probiotic use... yet, you have latched on to this single, solitary Israeli paper and take it as absolute gospel (even though it was tested on a product that makes no specific health claims).... because?.... oh yes.... because it suits your agenda!Sienna
siennadelekat21
17/10/2018
12:48
Pathetic question from our resident loser
What’s Opti got to do with UKOG Rayrac?
What have you as a non holder in Opti got to do with Opti Rayrac?

Now trot off to a bb where you actually hold some shares like UKOG or Bahamas
Doing well ain’t they?

judijudi
Chat Pages: Latest  1810  1809  1808  1807  1806  1805  1804  1803  1802  1801  1800  1799  Older

Your Recent History

Delayed Upgrade Clock